BioCentury
ARTICLE | Financial News

Trevi closes $15 million of $25 million series B

June 5, 2014 12:51 AM UTC

Dermatology company Trevi Therapeutics Inc. (New Haven, Conn.) raised $15 million in the first close of a $25 million series B round led by existing investor TPG Biotech. Trevi will use the funds to start two separate pivotal trials next quarter evaluating Nalbuphine ER to treat severe itch conditions uremic pruritus and prurigo nodularis. Top-line data from both trials are slated for 2H15. The company raised $10 million in a series A round in December 2012. ...